Notes from the Field: Meningeal and Pulmonary Tuberculosis on a Commercial Fishing Vessel — Hawaii, 2017

Erin K. Imada, MPH1; Emily K. Roberson, PhD2; Neela D. Goswami, MD3; Richard J. Brostrom3,4; Kathleen Moser, MD1; Kara Tardivel, MD1 (View author affiliations)

View suggested citation
Article Metrics
Altmetric:
Related Materials

In December 2016, U.S. Customs and Border Protection notified the CDC Honolulu Quarantine Station of a crewman on a commercial fishing vessel who was hospitalized with suspected tuberculosis (TB); the crewman, in his mid-30s, was unconsciousness, intubated, and dependent upon mechanical ventilation to maintain his respiratory status. He was a native of a high TB-burden country (one with TB incidence exceeding 10 cases per 100,000 population per year)* in the Pacific region. Nine days earlier, he had been hospitalized in Hawaii following a 1-month history of headache, fever, night sweats, chills, fatigue, weight loss, breathing difficulties, and cough and recent onset of abdominal pain, vomiting, dizziness, and blurred vision. Brain computerized tomography (CT) and magnetic resonance imaging scans showed lesions in the left basal ganglia and left temporal lobe; chest CT showed multiple bilateral lung opacities with central cavitation. Pathology results from a lung biopsy demonstrated acid-fast bacilli with molecular and culture tests positive for Mycobacterium tuberculosis complex, susceptible to all first-line drugs. Cerebrospinal fluid demonstrated low glucose (23 mg/dL), elevated protein (247 mg/dL), and elevated white blood cell count (298 cells/uL) with a relative lymphocytic predominance (50%), consistent with TB meningitis. Testing for human immunodeficiency virus infection was negative, and the patient had no medical comorbidities. The Hawaii Department of Health (Hawaii DOH) was contacted to assist with the investigation.

Upon confirmation of infectious TB, U.S. Customs and Border Protection, accompanied by the Hawaii Harbor Police called the vessel to port for contact interviews and TB screening by the CDC Honolulu Quarantine Station and Hawaii DOH. The vessel’s crew members included the captain, who was a U.S. citizen, and five crew members from the same country as the patient. A fisheries observer with the National Oceanic and Atmospheric Administration, who was a U.S. citizen, was identified as an additional contact. All seven contacts were evaluated by Hawaii DOH; none reported symptoms or signs of active TB. Four crew members had positive tuberculin skin test readings. These four persons were evaluated by Hawaii DOH and had normal chest x-rays, indicating that they had latent TB infection (LTBI). All four were offered LTBI treatment by Hawaii DOH, but all declined. The patient received standard four-drug treatment while hospitalized, regained consciousness and survived respirator-weaning but remained neurologically incapacitated. He completed 12 months of TB treatment. After 426 days, he was repatriated to his country of origin.

Meningeal TB is the most severe form of TB and is associated with high morbidity (5%–24%) (e.g., stroke, seizure, hydrocephalus, vision impairment, and hearing impairment) and mortality (10%–20%), even in high-resource countries (1). Infection of the central nervous system occurs by hematogenous dissemination of Mycobacterium tuberculosis from the lungs (2). Neurologic complications are most common when diagnosis and treatment are delayed (2,3).

This case highlights the clinical importance of considering TB in persons from high TB-burden countries. Meningeal TB should be suspected in patients who have signs and symptoms of TB disease (e.g., fever, chills, night sweats) as well as neurologic disease (e.g., headache, blurred vision, dizziness) without a plausible alternative diagnosis by history, physical exam, and basic laboratory or radiographic studies. Once extrapulmonary TB is confirmed, an evaluation for pulmonary disease should proceed (4). This patient’s delay of >1 month before being evaluated by a health care provider and his resultant neurologic incapacitation highlight the importance of early diagnosis and the challenges associated with accessing health care among mobile populations. Commercial, noncruise maritime crew members might be particularly vulnerable because of their remote locations, lack of onboard medical resources, and possible inadmissibility to the nearest port of entry. Crew members on commercial vessels are also at high risk for infection if exposed to communicable disease on board because of their close living and working conditions.

A number of factors affect initiation of LTBI therapy in mobile populations, including provider communication about treatment for LTBI versus active disease, barriers to access LTBI therapy, duration of treatment, financial and medical risk of medications, patient willingness to accept therapy, and provider willingness to prescribe treatment given the risk for loss to follow-up. Approximately 4%–6% of persons with untreated LTBI will develop infectious TB (4). Although the four contacts with LTBI declined treatment, this contact investigation demonstrates the feasibility of successful evaluation and management of TB close contacts even in challenging settings.

Acknowledgments

U.S. Customs and Border Protection, Port of Honolulu; Hawaii Department of Health; Pacific Islands Regional Office Observer Program, National Marine Fisheries Service, National Oceanic and Atmospheric Administration; Hawaii Harbor Police, Hawaii Department of Transportation.

Corresponding author: Erin K. Imada, ioo6@cdc.gov, 808-282-4359.


1Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 2Hawaii Pacific University, Honolulu, Hawaii; 3Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 4Hawaii Tuberculosis Control Program, Hawaii Department of Health.

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.


* Countries with the highest number of incident TB cases and that account for the highest global percentage of new TB cases. https://www.tbfacts.org/countries-tb/external icon.

References

  1. Merkler AE, Reynolds AS, Gialdini G, et al. Neurological complications after tuberculous meningitis in a multi-state cohort in the United States. J Neurol Sci 2017;375:460–3. CrossRefexternal icon PubMedexternal icon
  2. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008;21:243–61. CrossRefexternal icon PubMedexternal icon
  3. Brancusi F, Farrar J, Heemskerk D. Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome. Future Microbiol 2012;7:1101–16. CrossRefexternal icon PubMedexternal icon
  4. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 2017;64:e1–33. CrossRefexternal icon

Suggested citation for this article: Imada EK, Roberson EK, Goswami ND, Brostrom RJ, Moser K, Tardivel K. Notes from the Field: Meningeal and Pulmonary Tuberculosis on a Commercial Fishing Vessel — Hawaii, 2017. MMWR Morb Mortal Wkly Rep 2019;68:554–555. DOI: http://dx.doi.org/10.15585/mmwr.mm6824a5external icon.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In:pdf icon
Page last reviewed: June 20, 2019